Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
Phase 2 trial tests DS-1062a drug for advanced lung cancer with specific genetic changes
A Phase 2 interventional trial evaluated DS-1062a (6.0 mg/kg) in 137 participants with advanced/metastatic NSCLC with actionable genomic alt…
A completed Phase 2 trial tested DS-1062a for advanced lung cancer in 137 people who had already received prior chemotherapy and targeted th…
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
Meta-analysis: GOLD-PRISm prevalence 10.60%, GOLD-RSP 12.09% in general population
How common are hidden lung problems? A global review finds about 1 in 10 adults may have them
A multi-level meta-analysis of 48 studies (n=1,129,807) found the pooled prevalence of GOLD-defined preserved ratio impaired spirometry (PRI…
About 1 in 10 adults globally may have hidden lung problems linked to higher death risk, found in a review of over 1.1 million people.
Phase 2 Trial: Cytisine and ASA for Inflammation in Lifelong Smokers
Can quitting smoking and changing your diet really reduce lung inflammation?
A Phase 2 trial evaluates cytisine for smoking cessation and ASA for inflammation in 2000 lifelong smokers.
Quitting smoking, eating better, and moving more can reduce lung inflammation in lifelong smokers, offering a path to breathe easier and low…
Hyper-oncotic Albumin Reduces Mortality in ARDS Compared to Crystalloid
Could hyper-oncotic albumin save lives in patients with severe lung issues?
Meta-analysis shows hyper-oncotic albumin reduces mortality in ARDS (OR=0.61, CI 0.43-0.85) vs. crystalloid. RCTs show no benefit.
Patients with severe lung issues had lower death rates when given hyper-oncotic albumin instead of standard fluids, though results varied by…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
Could Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC.
A new trial tests if adding targeted liver radiation to standard drugs helps metastatic lung cancer patients live longer without disease pro…